<DOC>
	<DOCNO>NCT01216332</DOCNO>
	<brief_summary>This phase I safety immunogenicity trial compare high-dose ( HD ) trivalent inactivate influenza vaccine ( TIV ) standard dose ( SD ) TIV pediatric patient Acute Lymphoblastic Leukemia .</brief_summary>
	<brief_title>Standard Versus High-Dose Trivalent Inactivated Flu Vaccine Pediatric Acute Lymphoblastic Leukemia Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Pediatric patient standard high risk Acute Lymphoblastic Leukemia . Must 1st complete remission . Must 4 week maintenance therapy . 17 year age , inclusive . Available duration study . History hypersensitivity previous influenza vaccination hypersensitivity eggs/egg protein . History GuillainBarre syndrome . Evidence relapse disease . Have condition would , opinion site investigator , place unacceptable risk injury render unable meet requirement protocol . Have condition investigator believe may interfere successful completion study . History receive 2010 2011 influenza vaccine . Pregnant female . History proven influenza disease September 1 , 2010 .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>